Validation of a Mucosal IgA Assay for SARS-CoV-2
Microorganisms · 20.05.2026 · 14 (5) · 1154
DOI: 10.3390/microorganisms14051154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 20.05.2026. Verfasst von Mingzhu Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology, Novavax, Gaithersburg, MD 20878, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novavax (United States), Novavax, Inc..
Abstract (Originalsprache)
Mucosal immunity, including antibodies like immunoglobulin A (IgA), function as the body’s first line of defense in the respiratory tract, particularly against viruses. An anti-rS protein IgA enzyme-linked immunosorbent assay (ELISA) was developed using the Omicron XBB.1.5 subvariant of SARS-CoV-2 and was validated to demonstrate the suitability of the method for testing saliva from SARS-CoV-2 vaccine clinical trials. This assay successfully met acceptance criteria for inter-/intra-assay precision, specificity, selectivity, linearity, lower/upper limits of quantitation, and assay robustness. The IgA in saliva was stable for up to 7 freeze/thaw cycles, for up to 48 h at 24 °C, up to 7 days at 4 °C, up to 3 weeks at −20 °C, and up to 1 year at −80 °C. After validation using Omicron XBB.1.5 rS protein, cross-reactivity was demonstrated with the SARS-CoV-2 variant JN.1. This validated IgA assay can be a valuable tool to assess mucosal IgA levels in SARS-CoV-2 clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Immunology, Novavax, Gaithersburg, MD 20878, USA.
- Biostatistics, Novavax, Gaithersburg, MD 20878, USA.
- Clinical Development, Novavax, Gaithersburg, MD 20878, USA.
ORCID-Profile: Mingzhu Zhu, Urvashi Patel
Förderung
- Novavax (United States)
- Novavax, Inc.
Zitieren
APA
Zhu, M., Massuda, E., Cloney-Clark, S., Patel, U., Parekh, A., Gorinson, A., Klindworth, A., Ahmadi, A., Cai, M. R., Bennett, C., Kalkeri, R., & Plested, J. S. (2026). Validation of a Mucosal IgA Assay for SARS-CoV-2. Microorganisms, 14(5), 1154. https://doi.org/10.3390/microorganisms14051154
Vancouver
Zhu M, Massuda E, Cloney-Clark S, Patel U, Parekh A, Gorinson A, et al. Validation of a Mucosal IgA Assay for SARS-CoV-2. Microorganisms. 2026;14(5):1154. doi:10.3390/microorganisms14051154
BibTeX
@article{Zhu2026,
author = {Zhu, Mingzhu and Massuda, Edmond and Cloney-Clark, Shane and Patel, Urvashi and Parekh, Anand and Gorinson, Andrew and Klindworth, Andrew and Ahmadi, Ali and Cai, Miranda R and Bennett, Chijioke and Kalkeri, Raj and Plested, Joyce S},
title = {Validation of a Mucosal IgA Assay for SARS-CoV-2},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {5},
pages = {1154},
doi = {10.3390/microorganisms14051154}
}
EUVIMED